AstraZeneca to publish full US test results after rare backlash on ‘old-fashioned’ data

The rare public recall marks the latest hurdle for the vaccine when it was declared a milestone in the fight against COVID-19 pandemic disease but since then there have been questions in terms of efficacy and potential side effects.

AstraZeneca said results published Monday in which the vaccine confirmed 79% efficacy were based on an interim study of data through Feb. 17, and would now “immediately engage” with the independent panel overseeing the lawsuit to share the full analysis.

The British-based drug dealer said on Tuesday that it had reviewed the initial assessment of the full investigation, or primary, and that it was in line with the interim report.

But the Washington Post reported that the data review panel told federal officials that they had been working with the company through March, seeing data that showed the vaccine could be be 69% to 74% effective, and had “strongly recommended” AstraZeneca incorporate that information in its public statement.

AstraZeneca shares fell 1.8% in London trading.

The U.S. National Institute for Allergy and Infectious Diseases (NIAID) said Monday that the board responsible for ensuring the safety and accuracy of the test was concerned that the company may be taking its toll. included old-fashioned data that gave an incomplete view of the picture’s effectiveness.

Director of NIAID Dr. Anthony Fauci described the whole affair as an unfortunate unfortunate mistake.

“This is very likely a very good vaccine and this kind of thing doesn’t work … nothing but casts a little doubt on the vaccines and that could add to the laziness,” he told ABC’s “Good Morning America.”

“The data is very good but when they included it in the press release it was not entirely accurate,” he said.

In addition to the 79% effectiveness in stopping symbolic illness in the trial in the United States, Chile and Peru, the data reported Monday also showed that the bullet was 100% effective against severe or acute forms of the disease and that there was no greater danger. of blood clots.

Dr. Larry Corey, co-director of the U.S. Coronavirus Vaccine Prevention Network, which helped design the U.S. AstraZeneca test, said the retaliation of the review panel was something he had never seen before. The virologist at the Fred Hutchinson Cancer Research Center in Seattle praised the panel for speaking, saying it showed the system of checks and balances that was operated.

New doubts about the effectiveness of the missile are growing at the same time as it is being rolled out in dozens of countries and clouded the timeline for its potential emergency use permit in the United States.

“This is certainly an amazing act. The negative reports about this vaccine do not stop, although my assessment is that it is patient and safe, but clearly not as effective as the two mRNA vaccines,” said Peter Kremsner, of University Hospital. in Tuebingen, Germany.

Vaccines from Pfizer / BioNTech and Moderna that use messenger RNA (mRNA) technology to produce an immune response had both efficacy levels of about 95% in their critical clinical trials, well above the 50-day criterion. % set by global regulators.

AstraZeneca COVID-19 bulletproof has been facing questions since late last year when drug dealer and Oxford University published data from an earlier test with two different efficacy readings due to a dosing error .

Confidence in the vaccine took another blow this month, when more than a dozen countries, mostly in Europe, temporarily halted the issuance of the bullet after reports surfaced. linked to a rare bleeding disorder in a very small number of people.

The EU drugs regulator said last week that the vaccine was safe, but an opinion poll on Monday showed Europeans remained skeptical about its safety.

The most recent trial data, not yet reviewed by independent researchers or regulators, were based on 141 diseases among 32,449 participants.

Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, said the latest data request may be related to efficacy readings from recent cases, which may be introducing new viral changes and thus lower levels of protection.

“The other vaccines may be showing how effective they are and we don’t know how many,” he said.

The AstraZeneca vaccine is seen as an important factor in tackling the global spread of COVID-19 as it is easier and cheaper to carry than competitive strains.

Unconditional marketing or emergency use has been allowed in more than 70 countries.

Many countries rely heavily on the plan to end the pandemic, and a number of state leaders have publicly taken action to build confidence.